During the corresponding time, Apellis Pharmaceuticals Inc recorded a revenue increase by 60.85 % year on year, sequentially revenue grew by 34.21 %. While revenue at the Apellis Pharmaceuticals Inc 's corporate clients
Apellis Pharmaceuticals Inc's Comment on Sales, Marketing and Customers
The company provides treatment for patients with Paroxysmal Nocturnal Hemoglobinuria (PNH), a rare and chronic blood disorder. In May 2021, they launched EMPAVELI in the United States following FDA approval for PNH patients. Their sales efforts focus on healthcare professionals and key treatment centers managing patients experiencing breakthrough hemolysis, low hemoglobin, high fatigue, and transfusion requirements despite C5 inhibitor therapy. The market access team works with primary and secondary payors covering a substantial portion of PNH patients. The company estimates there are approximately 4,700 PNH patients in the U.S. and 15,000 worldwide. Additionally, they are developing a single-dose, sterilized prefilled syringe for SYFOVRE to facilitate administration by physicians, with regulatory submission planned for the first half of 2026.
Apellis Pharmaceuticals, Inc. has announced significant new findings regarding EMPAVELI (pegcetacoplan), a complement C3 inhibitor, based on data from the open-label period of the Phase 3 VALIANT study. These findings, which will be presented at the American Society of Nephrology (ASN) Kidney Week from October 23-27, 2024, in San Diego, CA, highlight the robust and sustained efficacy of EMPAVELI in treating patients with C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) two rare and debilitating kidney diseases.The VALIANT study, which previously yielded positive topline results in August 2024, marks a pivotal moment in research and treatment options for th...
In a significant development for patients with rare kidney diseases, Apellis Pharmaceuticals Inc. (NASDAQ: APLS) has announced that the U.S. Food and Drug Administration (FDA) has accepted its Supplemental New Drug Application (sNDA) for EMPAVELI (pegcetacoplan). The application seeks to expand the product s indications to include C3 glomerulopathy (C3G) and primary immunoglobulin M (IgM) nephropathy (MPGN). This acceptance, coupled with a designation for priority review, highlights the potential of EMPAVELI to address unmet medical needs in patients suffering from debilitating kidney conditions.C3G and primary IgM-MPGN are rare kidney disorders characterized by the deposition of complement components in the...
In an era where the pharmaceutical landscape is increasingly driven by groundbreaking innovations, Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) has emerged as a paradigmatic example. The Waltham, Massachusetts-based biotech firm recently unveiled promising data from its GALE long-term extension study, confirming that its leading drug candidate, SYFOVRE (pegcetacoplan injection), preserved visual function at 36 months in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Presented at the Clinical Trials at the Summit (CTS) Meeting on June 8 in Park City, Utah, these findings could spell a new chapter in the treatment of this debilitating eye condition. Preservation of V...
Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA CongressWALTHAM, Mass. and STOCKHOLM, Sweden, May 24, 2024 - Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi(STO:SOBI) have announced encouraging one-year results from the Phase 2 NOBLE study evaluating the use of systemic pegcetacoplan, a targeted C3 therapy, in the treatment of post-transplant recurrence of C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). These findings were presented during a late-breaking oral presentation at the European Renal Association (ERA) Congress held from May 23-26 in Stockholm, Sw...
Investigation Alert: Johnson Fistel, LLP Explores Potential Violations by Cummins, Apellis Pharmaceuticals, Inspire Medical, and Applied DigitalSan Diego-based shareholder rights law firm, Johnson Fistel, LLP, has announced an investigation into potential violations of federal and state laws by certain officers of Cummins Inc. (NYSE: CMI), Apellis Pharmaceuticals, Inc. (NASDAQ: APLS), Inspire Medical Systems, Inc. (NYSE: INSP), and Applied Digital Corporation (NASDAQ: APLD). The firm encourages long-term investors to reach out for more information regarding this matter.This investigation comes at a time when Apellis Pharmaceuticals Inc. has recorded a substantial revenue increase. According to recent data, t...
WALTHAM, Massachusetts, April 26th, 2024 Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announces a significant step forward in its journey, redefining the dynamism of the pharmaceutical sector. The European Medicines Agency (EMA) has declared a reset of the review of the Marketing Authorization Application (MAA) for intravitreal pegcetacoplan, the investigational medication designed for the treatment of geographic atrophy.Revised Timelines and Anticipated ResultsThe EMA has strategically reset the calendar for the MAA review to day 180, marking the final stage in the initial assessment process. The rescheduling of the MAA evaluation signifies the rigorous examination and potential perfected approval of the ...
Apellis Pharmaceuticals, Inc., a leading biopharmaceutical company, recently announced its preliminary fourth-quarter and full-year net product revenues for 2023. The figures reveal significant success in the sales of its flagship drugs, SYFOVRE and EMPAVELI. Furthermore, the company witnessed an extraordinary revenue increase of 400.54% year on year and a sequential growth of 16.25%. This remarkable performance highlights Apellis strong market position and its dedication to addressing debilitating conditions such as geographic atrophy (GA) secondary to age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH). With such impressive results, Apellis Pharmaceuticals continues to pave the ...
Apellis Pharmaceuticals Inc’s Comment on Sales, Marketing and Customers
The company provides treatment for patients with Paroxysmal Nocturnal Hemoglobinuria (PNH), a rare and chronic blood disorder. In May 2021, they launched EMPAVELI in the United States following FDA approval for PNH patients. Their sales efforts focus on healthcare professionals and key treatment centers managing patients experiencing breakthrough hemolysis, low hemoglobin, high fatigue, and transfusion requirements despite C5 inhibitor therapy. The market access team works with primary and secondary payors covering a substantial portion of PNH patients. The company estimates there are approximately 4,700 PNH patients in the U.S. and 15,000 worldwide. Additionally, they are developing a single-dose, sterilized prefilled syringe for SYFOVRE to facilitate administration by physicians, with regulatory submission planned for the first half of 2026.
Sources:
Apellis Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Apellis Pharmaceuticals Inc’s corporate clients.
For your research, we’ve provided 9 tables on Apellis Pharmaceuticals Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
15.39 %